Associate Professor Jemma Hopewell
BSc (Hons) MSc PhD (Cantab)
Associate Professor & Senior Scientist in Genetic Epidemiology and Clinical Trials
- BHF Intermediate Basic Science Research Fellow
- MSc in Global Health Science Module Lead: Genetic Epidemiology
Associate Professor Jemma leads a medical statistics and genetic epidemiology team in a programme of research focusing on the use of genetic and clinical trial-based studies to investigate the causes and treatments for cardiovascular disease and arrhythmias. She has particular interests in determining predictors of patient response to therapy, using genetics to improve our understanding of drug targets and disease mechanisms, and genomic characterisation of vascular disease and its risk factors, particularly Lp(a). Jemma leads and collaborates on numerous projects involving CTSU's vascular mega-trials (e.g. HPS, SEARCH, THRIVE, REVEAL), large-scale studies and biobanks (e.g. PROCARDIS, UK Biobank), and international consortia (e.g. METASTROKE, CARDIoGRAMplusC4D, GoLEAD, CATCH-ME). She is a member of the Lp(a) Foundation Scientific Advisory Board, of various clinical trial and genetic study Steering and Analysis Committees, and is currently the Chair of METASTROKE (a collaboration of the International Stroke Genetics Consortium), as well as co-ordinating the MSc in Global Health Science Genetic Epidemiology module.
Independent risk factors for simvastatin-related myopathy and relevance to different types of muscle symptom.
Hopewell JC. et al, (2020), Eur Heart J
Identification of patients with atrial fibrillation: a big data exploratory analysis of the UK Biobank.
Oster J. et al, (2020), Physiol Meas, 41
Genetic determinants of blood lipids and cerebral small vessel disease: role of high-density lipoprotein cholesterol.
Georgakis MK. et al, (2020), Brain, 143, 597 - 610
Genome-Wide Association Study of Over One Million Participants Identifies 49 Novel Loci Associated With Coronary Artery Disease
Aragam KG. et al, (2019), CIRCULATION, 140
Impact of genetically determined differences in ECG parameters on risk of AF in c. 300,000 UK Biobank participants
Gajendragadkar PR. et al, (2019), EUROPEAN HEART JOURNAL, 40, 726 - 726